Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and MiMedx Group (MDXG)
TipRanks · 01/10 11:40
MIMEDX continues to see Q4 net sales in the ranges of $73M to $76M
Seeking Alpha · 01/09 14:41
BRIEF-MiMedx Group Confirms Q4 Net Sales Expected In The Ranges Of $73 Million To $76 Million
Reuters · 01/09 13:54
MIMEDX Confirms Q4 And FY22 Net Sales Expectations, Comments On Evolving Medicare Reimbursement Landscape And Provides Corporate Updates; Sees Q4 Revenue Between $73M-$76M; FY22 Revenue Between $266M-$269M
Benzinga · 01/09 13:18
MiMedx Reiterates Q4, 2022 Sales Outlook; Shares Rise
MiMedx Reiterates Q4, 2022 Sales Outlook; Shares Rise
MT Newswires · 01/09 11:37
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 01/04 21:30
MiMedx announces commercial launch of EPIFIX product in Japan with distribution deal
Seeking Alpha · 01/04 21:22
BRIEF-Mimedx Announces Commercial Launch Of Epifix In Japan
Reuters · 01/04 21:21
MIMEDX Announces Commercial Launch Of EPIFIX In Japan With Exclusive Distribution Agreement With GUNZE MEDICAL LIMITED
Benzinga · 01/04 21:02
MiMedx Sings Distribution Deal with Gunze Medical to Sell EPIFIX in Japan
MiMedx Sings Distribution Deal with Gunze Medical to Sell EPIFIX in Japan
MT Newswires · 01/04 17:12
BRIEF-MiMedx Announces Wound & Surgical Product Pipeline Expansion On Agreement With Turn Therapeutics
Reuters · 12/08/2022 14:35
MIMEDX Announces In-Licensing And Distribution Agreement With Turn Therapeutics; Uner Terms, MIMEDX 'has exclusive rights to develop future products for the wound care, burn, and surgical fields using Turn's IP.'
Benzinga · 12/08/2022 13:04
MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics
Agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion® proprietary antimicrobial intellectual property (IP), accelerating the product development pipeline for wound and surgical recovery applications MARIETTA, Ga., Dec. 08, 2022 (GLOBE NEWS...
GlobeNewswire · 12/08/2022 13:00
MiMedx Group Signs Licensing Deal with Turn Therapeutics
MiMedx Group Signs Licensing Deal with Turn Therapeutics
MT Newswires · 12/08/2022 12:42
MDXG: KOA Trial Launch Around the Corner
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT 3Q:22 Financial and Operational Results After market close on November 2, 2022, MiMedx Group, Inc. (NASDAQ:MDXG) filed its Form 10-Q with the SEC and issued a press release summarizin...
Zacks Small Cap Research · 11/03/2022 10:32
BRIEF-Mimedx Announces Third Quarter 2022 Results
Reuters · 11/02/2022 21:42
MiMedx Group GAAP EPS of -$0.09 in-line, revenue of $67.69M beats by $0.96M
Seekingalpha · 11/02/2022 20:51
MiMedx Group Q3 EPS $(0.09) Misses $(0.08) Estimate, Sales $67.69M Beat $66.73M Estimate
Benzinga · 11/02/2022 20:49
-- GUIDANCE: (MDXG) MIMEDX GROUP Sees Q4 Revenue Range $67.7M
-- GUIDANCE: (MDXG) MIMEDX GROUP Sees Q4 Revenue Range $67.7M
MT Newswires · 11/02/2022 16:40
MiMedx Group Q3 2022 Earnings Preview
Seekingalpha · 11/01/2022 21:35
Webull provides a variety of real-time MDXG stock news. You can receive the latest news about Mimedx Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MDXG
MiMedx Group, Inc. is a transformational placental biologics company, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.